Navigation Links
Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access Conference
Date:8/7/2013

THE WOODLANDS, Texas, Aug. 7, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Wedbush PacGrow Life Sciences Management Access Conference on Tuesday, August 13, at 1:20 PM ET in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until September 13, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
2. Lexicon to Report Second Quarter Financial Results on July 30, 2013
3. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
4. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
5. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
6. Lexicon To Present At The Jefferies Global Healthcare Conference
7. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
9. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
10. Lexicon to Report First Quarter Financial Results on May 10, 2013
11. Lexicon To Present At The Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... YORK , May 27, 2016 ... biotechs, drug manufacturers, health insurance companies all falling under ... small healthcare companies. While not often talked about, these ... The United States is by far ... world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. ...
(Date:5/26/2016)... -- Since its commercial introduction in 2005, ... science tool for conducting genetic studies in a range ... its new report that the industry sits on the ... a range of new applications in the clinical diagnostics ... ) , Since the Human Genome ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and ... members: , David G. Lewallen, MD, began his term as president in March, ... L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as ...
(Date:5/31/2016)... ... 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of three ... and Shore Medical Center – Somers Point, NJ. The new clients range in bed ... the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a leading ...
(Date:5/31/2016)... ... ... In a recent interview on The Greenburgh Report radio show hosted by ... (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues ... , During the interview with Mr. Feiner that aired on May 7, 2016, ...
(Date:5/31/2016)... ... 2016 , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry ... of 1986, where he graduated in the top ten percentile of his class. Dr. ... 1989. He has been a member in good standing for thirty years in the ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... to apply information technology solutions to the healthcare industry, The University of Scranton ... program offers an accelerated path to a career in rapidly growing field of ...
Breaking Medicine News(10 mins):